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Abstract
Background: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and 
pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a 
humanized RSV monoclonal antibody (MAb). In preclinical in vitro and in vivo (cotton-rat model) studies, motavizumab, 
a new RSV MAb, was shown to have greater anti-RSV activity than palivizumab. Motavizumab is currently under review 
for licensing approval. Since both MAbs may be available concurrently, this study evaluated their safety and tolerability 
when administered sequentially during the same RSV season.
Methods: Between April 2006 and May 2006, 260 high-risk infants were randomly assigned 1:1:1 to receive monthly 
intramuscular injections: 2 doses of motavizumab followed by 3 doses of palivizumab (M/P); 2 doses of palivizumab 
followed by 3 doses of motavizumab (P/M); or 5 doses of motavizumab (control). Adverse events (AEs, serious AEs 
[SAEs]), development of antidrug antibody (ADA), and serum drug trough concentrations were assessed.
Results: Most children received all 5 doses (246/260 [94.6%]) and completed the study (241/260 [92.7%]). While overall 
AE rates were similar (mostly level 1 or 2 in severity), SAEs and level 3 AEs occurred more frequently in the M/P group 
(SAEs: 22.9% M/P, 8.4% P/M, 11.8% motavizumab only; level 3 AEs: 15.7% M/P, 6.0% P/M, 6.5% motavizumab only). This 
trend in AE rates occurred before and after switching from motavizumab to palivizumab, suggesting a cause other 
than the combined regimen. Frequencies of AEs judged by the investigator to be related to study drug were similar 
among groups. Two deaths occurred on study (both in the M/P group, before palivizumab administration); neither was 
considered by the site investigator to be related to study drug. Mean serum drug trough concentrations were 
comparable among groups; ADA detection was infrequent (5.1% or less of any group).
Conclusions: The conclusions drawn from this study are limited by the small sample size per group. However, within 
this small study, overall AE rates, serum drug trough concentrations, and development of ADA associated with 
administering motavizumab and palivizumab sequentially to high-risk children appear comparable to administering 
motavizumab alone during the same RSV season.
Trial Registration: clinicaltrials.gov NCT00316264
Background
Respiratory syncytial virus (RSV) is an important respira-
tory pathogen that produces annual epidemics of bron-
chiolitis and pneumonia in young children worldwide [1-
3]. The greatest morbidity and mortality occur among
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children a t high ris k for severe RSV disease, including
premature infants, infants with chronic lung disease
(CLD), and infants with complicated congenital heart dis-
ease [4-6].
These high-risk infants currently receive prophylaxis
for RSV with palivizumab (MedImmune, Gaithersburg,
MD, USA), which is recommended and indicated for the
prevention of severe RSV disease in high-risk children
[7,8]. Palivizumab is a humanized monoclonal antibody
that recognizes a highly conserved neutralizing epitope in
the A antigenic site of the F glycoprotein of RSV [9].
Monthly palivizumab administration has been shown to
reduce RSV hospitalizations by approximately 50% com-
pared with placebo in high-risk children with prematu-
rity, CLD of prematurity, and congenital heart disease
[10-12]. In addition, in the IMpact study, preterm infants
without CLD who received prophylaxis with palivizumab
had an even greater reduction in RSV-related hospitaliza-
tions that approached 80% [12].
Motavizumab (MEDI-524, MedImmune) is an investi-
gational monoclonal antibody developed by affinity mat-
u r a t i o n  o f  p a l i v i z u m a b .  C o m p a r e d  w i t h  p a l i v i z u m a b ,
motavizumab has an approximately 75-fold greater affin-
ity for the RSV F protein [13,14], is approximately 20-fold
more active in microneutralization studies, and, in the
cotton rat model, reduces nasal and lung RSV titers 25-
and 100-fold, respectively [14,15]. In comparison with
controls, in a mouse model of RSV, motavizumab was
also found to be associated with significant reductions in
RSV replication and concentrations of cytokines (inter-
leukin-1 alpha, interleukin-12p70 and tumor necrosis
factor alpha, interferon gamma) that are probably related
to improvements observed in clinical markers of disease
severity [16].
Early pediatric clinical studies of motavizumab in
which children received monthly intramuscular dosing
demonstrated no dose-limiting toxicities, and serum
pharmacokinetics were found to be consistent with pub-
lished data for palivizumab [17,18]. In addition, in a
proof-of-concept phase 1 study, children hospitalized
with RSV illness were given a single dose of intravenous
motavizumab or placebo [18]. In that study, motavizumab
significantly reduced viral load and culturable RSV was
eliminated 1 day post-treatment in a greater proportion
of treated children compared to those who received pla-
cebo. Significant anti-RSV effects were not seen in the
upper respiratory tracts of infants in a similar study con-
ducted with palivizumab [19]. Recently, a large clinical
study of over 6600 infants[20] to evaluate monthly immu-
noprophylaxis during the RSV season with motavizumab
compared to palivizumab was completed. In this study of
premature infants with and without CLD, motavizumab
was shown to be noninferior to palivizumab with a 26%
relative reduction in the primary endpoint of RSV hospi-
talizations (1.4% vs 1.9%, respectively; relative risk, 0.740;
95% confidence interval: 0.503, 1.083) [20]. In addition, in
the outpatient setting, a secondary endpoint, motavi-
zumab was superior to palivizumab, effecting a 50% rela-
tive reduction of RSV-specific, medically attended, lower
respiratory tract infections (2.0% vs 3.9%, respectively; P
= 0.005) [20].
Motavizumab is currently under review by the US Food
and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in children
at high risk of RSV disease. Because it is likely that ini-
t i a l l y  b o t h  p r o d u c t s  w i l l  b e  a v a i l a b l e  c o n c u r r e n t l y  f o r
commercial use, there could be times when a child
receives both agents sequentially within the same RSV
season. Therefore, the primary objective of this study was
to provide initial data on the safety of motavizumab and
palivizumab when administered sequentially to high-risk,
preterm infants during the same RSV season. Additional
objectives of the study were to determine serum trough
concentrations of motavizumab and palivizumab when
administered during the same RSV season and to evalu-
ate the development of antimotavizumab and antipalivi-
zumab antidrug antibodies (ADA).
Methods
Study Design
This was a phase 2, randomized, double-blind study in
which motavizumab and palivizumab were administered
during the same RSV season to premature infants with
and without CLD. The study was conducted between
April 2006 and February 2007. During the 2006 RSV sea-
son, eligible infants were enrolled at 18 sites in the south-
ern hemisphere, which included Chile (7 sites), New
Zealand (5 sites), and Australia (6 sites). Eligible children
were randomly assigned (1:1:1, stratified by site) to one of
3 treatment groups using an automated randomization
system: 2 doses of motavizumab followed by 3 doses of
palivizumab (M/P); 2 doses of palivizumab followed by 3
doses of motavizumab (P/M); or 5 doses of motavizumab
only (control). Motavizumab and/or palivizumab were
administered at 15 mg/kg by intramuscular injection
every 30 days, for a total of 5 planned doses. These are the
prescribed dose and regimen as currently used for palivi-
zumab. Doses were administered on study days 0, 30, 60,
90, and 120. Drug administration of dose 2 (day 30) was
allowed between day 25 and day 30. For all other doses, a
prespecified ± 5-day window was allowed.
The study was conducted in accordance with the Decla-
r a t i o n  o f  H e l s i n k i  a n d  i n  c o m p l i a n c e  w i t h  t h e  e t h i c a l
principles of the International Conference on Harmoni-
zation Guidelines for Good Clinical Practice. The study
was approved by the institutional review board or inde-
pendent ethics committee of each participating center.Fernández et al. BMC Pediatrics 2010, 10:38
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Parents or legal guardians provided written informed
consent for each subject before enrollment.
Study Endpoints
The primary endpoints were safety and tolerability of
motavizumab and palivizumab administered sequentially
during the same RSV season, as assessed by summarizing
adverse events (AEs), serious AEs (SAEs), and laboratory
evaluations. Secondary endpoints were ADA and serum
trough concentrations of motavizumab and palivizumab.
AEs were defined as any unfavorable and unintended sign
(including an abnormal laboratory finding), symptom, or
disease that occurred while the child was enrolled in the
study from the time of randomization through study day
150, whether or not the event was considered to be
related to the study treatment. SAEs were defined as AEs
that resulted in death, risk of life, hospitalization or pro-
longation of existing hospitalization, persistent or signifi-
cant disability or incapacity, or that required medical or
surgical intervention to prevent any of these outcomes.
AEs and SAEs were summarized by system organ class
and preferred terms using the Medical Dictionary for
Regulatory Activities (MedDRA), by severity (levels 1-4,
which corresponded to mild, requiring no treatment;
moderate, possibly requiring symptomatic therapy;
severe, generally requiring a more immediate medical
evaluation or treatment; and life-threatening, requiring
immediate medical attention to support vital functions,
respectively), and by relationship to study treatment
(none, remote, possible, probable, definite). AEs were
assessed by the investigator for severity, relationship to
the study treatment, and whether the event met criteria
as an SAE (ie, not all level 4 AEs, such as laboratory
abnormalities, met criteria for SAE). All summaries of
AEs include both nonserious AEs and SAEs.
Study Inclusion and Exclusion Criteria
Preterm children were eligible to participate if the gesta-
tional age was ≤35 weeks and the chronologic age was ≤6
months at the time of entry into the study, or if they were
≤24 months of age at the time of entry into the study and
had a diagnosis of CLD of prematurity requiring medical
management within 6 months before randomization. Eli-
gible children had to be in good health at the time of
study entry. They could not be hospitalized (unless dis-
charge was expected within 10 days); be receiving chronic
oxygen therapy or any ventilatory support; have signifi-
cant congenital heart disease; have evidence of infection
with hepatitis A, B, or C virus or HIV; have any acute ill-
ness, including acute RSV infection; known renal impair-
ment, hepatic dysfunction, chronic seizure disorder, or
immunodeficiency; have suspected serious allergic or
immune-mediated events in association with prior
receipt of immunoglobulins, blood products, or other
foreign proteins; have received within the past 120 days
or currently be receiving immunoglobulin products,
palivizumab, or any investigational agent.
Study Assessments
S u b jects  w e r e  eva l u a t ed  be f o r e  e a c h  i n j ect i o n  o f  s t u d y
drug, at study day 150, which corresponded to 30 days
after the fifth and final planned dose of study drug, and at
the final follow-up visit between study days 270 and 300,
which corresponded to 120 to 150 days after the fifth
dose of study drug. Subjects were monitored for AEs and
SAEs from the time of the first study drug administration
through study day 150. Blood was collected to assess
serum drug trough concentrations and development of
ADA on day 0 (pre-drug baseline), day 60 (before dose 3),
and day 150. Final assessments of antimotavizumab and
antipalivizumab antibody and serum trough concentra-
tions of motavizumab and palivizumab were performed
between study days 270 and 300.
Enzyme linked immunosorbent assays to quantify
ADAs and trough serum concentrations of motavizumab
and palivizumab were developed by MedImmune and
validated and performed by PPD Development, LP (Rich-
mond, VA). These methods have been described previ-
ously [9,17]. No data on the prevention of RSV disease
were collected.
Study Products
Study drugs were provided in sterile, preservative-free
vials containing 100 mg motavizumab in 1 mL 25 mM
histidine-HCL, pH 6.0, or 100 mg palivizumab in 1 mL 25
mM histidine, 1.6 mM glycine, pH 6.0. Both study prod-
ucts were stored at 2° to 8°C. Motavizumab was adminis-
tered at the same prescribed dose and regimen as is
currently used for palivizumab (15 mg/kg administered
by intramuscular injection at monthly intervals for 5
months).
Statistical Methods and Analysis Populations
As no hypothesis testing was planned to compare treat-
m e n t s ,  n o  f o r m a l  s a m p l e  s i z e  c a l c u l a t i o n s  w e r e  p e r -
formed. However, AE rates were compared between
treatment groups using a 2-sided Fisher's exact test to
note significant differences. Statistically significant differ-
ences were reported for P values < 0.05. Given the num-
ber of subjects enrolled and included in the safety
analyses, the minimum statistical difference that could
have been detected with 80% power between the control
arm (N = 93) and either mixed-dose arm (N = 83) was 10
percentage points for event rates of 1.0% and 22 percent-
age points for event rates of 50%. For example, if one
treatment group had an event rate of 1%, an event rate of
at least 11% would have been necessary in the compari-
son treatment group to allow at least an 80% chance of
detecting a statistically significant difference between theFernández et al. BMC Pediatrics 2010, 10:38
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two treatment groups. Similarly, if one treatment group
had an event rate of 50%, an event rate of at least 72%
would have been necessary in the comparison treatment
group. Due to the number of tests that were performed,
the  P  values should be interpreted with caution. No
adjustments for multiple comparisons were made.
Statistical analyses were performed using SAS/STAT®
Version 8.2. Categorical data are summarized by the
number and percent of subjects in each category. Contin-
uous variables are summarized by descriptive statistics
including mean, standard deviation, minimum, and maxi-
mum. Study day 0 was defined as the day of randomiza-
tion.
The intent-to-treat population included all randomized
subjects. The safety population included all randomized
subjects who received study drug and had any safety fol-
low-up. The serum drug trough concentration and ADA
population included all subjects in the safety population
who did not receive commercial palivizumab during the
120 days before study day 0. Subjects were excluded from
any individual time-point summary of serum drug trough
concentration and ADA if they did not receive the correct
number of study treatment doses before that time point.
Results
Study Population
A total of 260 subjects were enrolled into the 3 treatment
groups during April and May 2006: M/P, n = 83; P/M, n =
84; and motavizumab only (control), n = 93; 259 subjects
received at least one dose of study drug. Demographic
characteristics at study entry are presented in Table 1.
Overall, the treatment groups were balanced with respect
to chronologic age, weight, and gestational age. There
were 2 minor imbalances noted that were not felt to affect
the outcome of the study: 1) the baseline incidence of
CLD was slightly lower in the M/P treatment group
(13.3%) than in the P/M and motavizumab-only (control)
treatment groups (16.7% and 17.2%, respectively); and 2)
there were slightly more male subjects enrolled in the M/
P treatment group (61% in M/P compared with 51% and
52% in the P/M and the motavizumab-only [control]
groups, respectively).
Subject Compliance, Disposition, and Discontinuations
Subjects who remained in the study for the final follow-
up visit between study days 270 and 300 were deemed to
have completed the study. The majority (246/260, 94.6%)
of subjects received all 5 doses of study drug, and a total
of 241/260 (92.7%) subjects completed the study (Figure
1). Two children who had study drug discontinued due to
SAEs continued with follow-up until the completion of
the study; both were in the M/P group (one developed
erythema multiforme after 2 doses; another developed
staphylococcal scalded skin syndrome after 3 doses).
Another child who discontinued study drug after an SAE
of visual disturbance (also in the M/P group) after receiv-
ing 1 dose of study drug did not continue in the study. All
3 of these children were included in the safety population.
One subject assigned to the P/M treatment group did not
receive study drug and was therefore not included in the
safety, ADA, or serum drug trough concentration analy-
ses.
Table 1: Demographic characteristics at study entry
Characteristic Mixed Motavizumab/
Palivizumab (n = 83)
Mixed Palivizumab/
Motavizumab (n = 84)
Motavizumab 
Only (n = 93)
Total (N = 260)
Age, mo
Mean (SD) 3.7 (3.1) 3.4 (2.3) 3.9 (2.4) 3.7 (2.6)
Gestational age at birth, wk
Mean (SD) 31.0 (2.6) 31.3 (2.9) 30.9 (2.7) 31.1 (2.7)
Sex, n (%)
Male 51 (61.4) 43 (51.2) 48 (51.6) 142 (54.6)
Race/ethnicity, n (%)
White/Non-Hispanic 23 (27.7) 20 (23.8) 28 (30.1) 71 (27.3)
Hispanic 53 (63.9) 56 (66.7) 57 (61.3) 166 (63.8)
Other 7 (8.4) 8 (9.5) 8 (8.6) 23 (8.8)
Weight, kg
Mean (SD) 4.6 (2.0) 4.4 (1.8)a 4.7 (1.7) 4.6 (1.8)
CLD present, n (%) 11 (13.3) 14 (16.7) 16 (17.2) 41 (15.8)
an = 83 (weight was not recorded for one subject).Fernández et al. BMC Pediatrics 2010, 10:38
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Safety: Adverse Events
A comparative overview of AEs for the 3 groups overall
and by severity is presented in Table 2. Overall, 89% to
93% of subjects in all 3 groups experienced at least 1 AE.
In general, AE rates were similar among the treatment
groups, with the exception of level 3 events reported as
the highest severity and SAEs, for which the M/P treat-
ment group had more subjects with these events than the
other 2 groups. In the M/P group, 15.7% reported at least
one level 3 AE, compared with 6.0% in the P/M group and
6.5% in the motavizumab-only (control) group. The inci-
dence of level 3 and level 4 AEs in the M/P group was sig-
nificantly higher compared with the P/M group (19.3%
vs. 6.0%, respectively; P < 0.05) but did not differ signifi-
cantly from the rate in the motavizumab-only (control)
group (10.8%). More than half of level 3 or level 4 events
in any treatment group (15/17, 5/7, and 6/10 events in the
M/P, P/M, and motavizumab-only [control] groups,
respectively) were classified in the MedDRA "infections
and infestations" system organ class. A total of 24 SAEs
occurred in 19 children in the M/P group, 9 SAEs
occurred in 7 children in the P/M group, and 12 SAEs
occurred in 11 children in the motavizumab-only (con-
trol) group (Table 2).
Overall, the types and numbers of specific AEs were
similar among the 3 treatment groups; those occurring in
at least 5% of subjects in any group are summarized in
Table 3. The most frequent AEs were infectious in nature
and were expected for this population of high-risk chil-
dren. The most commonly reported AEs included
nasopharyngitis, upper respiratory infection, wheezing,
conjunctivitis, teething, rhinitis, diarrhea, and bronchitis.
Most AEs in any treatment group were level 1 or 2 in
severity (M/P, 388/405 [95.8%]; P/M, 401/408 [98.3%];
and motavizumab only [control], 449/459 [97.8%]).
Due to the higher frequencies of level 3 AEs (as the
highest severity) and SAEs in the M/P treatment group, a
post hoc analysis was performed to determine the inci-
dence of AEs before and after receipt of dose 3 (when the
switch to the second study drug occurred). It is important
to note that the reporting period for this analysis encom-
passed 60 days before dose 3 and 90 days after dose 3. An
overview of safety data before and after dose 3 is pre-
sented in Table 4. The increases in level 3 or 4 AEs and
SAEs were consistently observed both before and after
dose 3 in the M/P group. After 2 doses of study drug (ie,
prior to dose 3), all groups had comparable rates of AEs
and AEs deemed by the site investigators to be related to
Figure 1 Subject disposition through the end of the study period. aIntent-to-treat population. bIncludes 1 subject with an SAE of visual distur-
bance who discontinued drug after 1 dose and did not complete the study; 2 additional subjects discontinued drug after receiving < 5 doses of study 
drug (1 with erythema multiforme after 2 doses and 1 with staphylococcal scalded skin syndrome after 3 doses, both in the M/P group), but since they 
were followed through the end of the study period are classified as having completed the study, thus they are not included in this total. cIncludes 1 
subject for whom consent was withdrawn on day 13 and who died of a bowel obstruction on day 153. dCompleted the study through study days 270-
300 (120-150 days after the final dose).
Enrolled and Randomizeda
N=260
n=91 (97.8%)
Completed Studyd 
n=87 (93.5%)
 6  (6.5)
Motavizumab/Palivizumab
n=83
Palivizumab/Motavizumab
n=84
n=76 (91.6%)
Completed Studyd
n=77 (92.8%)
n=79 (94.0%)
Completed Studyd 
n=77 (91.7%)
 6  (7.2)  b
Withdrawal of consent 3  (3.6)
Death 2  (2.4)
Possibly related
SAE after dose 1 1  (1.2)
Withdrawal of consent 6 (6.5)  c
  7 (8.3)
Relocation 1  (1.2)
5  (6.0) Withdrawal of consent
Lost to follow-up 1  (1.2)
Motavizumab
n=93
Discontinued, n (%)
Received 5 doses Received 5 doses Received 5 doses
Discontinued, n (%) Discontinued, n (%)Fernández et al. BMC Pediatrics 2010, 10:38
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study treatment. Before dose 3, the rates of level 3 AEs as
the highest severity, level 4 AEs, SAEs, SAEs judged by
the investigator to be related to study drug, and AEs
resulting in discontinuation of study drug were all higher
among children in the M/P group than in the motavi-
zumab-only (control) treatment group. Some of these dif-
ferences persisted after receipt of dose 3 of study drug,
with the M/P group exhibiting higher rates of level 3 AEs
(as the highest severity) and SAEs compared with either
the motavizumab-only (control) or the P/M treatment
group. The number of children who experienced SAEs
before and after dose 3 was similar for both dosing peri-
ods in each group. In the M/P group, 14 of the 24 SAEs
were level 3 or level 4 in severity; similarly, 14 of the 17
level 3 or level 4 AEs were considered SAEs. In the P/M
group, 4 of the 9 SAEs were level 3 in severity; likewise, 4
of the 7 level 3 AEs were considered SAEs. No level 4 AEs
w e r e  r epo rt ed  i n  t h is  gr o u p .  I n  t h e  m o t a viz u m a b - o n l y
(control) group, 7 of the 12 SAEs were level 3 or level 4 in
severity; similarly, 7 of the 10 level 3 or level 4 AEs were
considered SAEs. At least one-half of SAEs in any treat-
ment group (19/24 in the M/P group, 7/9 in the P/M
group, 6/12 in the motavizumab-only [control] group)
were infection-related. In the M/P group, a total of 12 of
24 SAEs occurred after receipt of dose 3 (ie, when sub-
jects had received both study drugs). All 12 were infec-
tious in nature, and 11 of the 12 were respiratory
infections. Ten of the 11 respiratory infections had local
viral testing performed, with only 2 tests positive for Rsv.
Adverse Events Judged by the Site Investigators as Related 
to Study Treatment
Overall, the frequencies of AEs deemed by the investiga-
tor to be related to treatment with palivizumab or mot-
avizumab were comparable among all 3 treatment groups
(M/P, 16.9%; P/M, 19.3%; motavizumab only [control],
22.6%). The 2 most common AEs judged by the investiga-
tor to be related to study drug were injection-site ery-
thema (M/P, 2.4%; P/M, 10.8%; motavizumab only, 8.6%)
and irritability (4.8%, 7.2%, and 7.5%, respectively). The
rate of injection-site erythema was significantly lower in
the M/P group compared with the P/M group (P < 0.05),
and the events were balanced before and after dose 3.
These AEs were all level 1 in severity except in 2 subjects
in the M/P group, each of whom experienced 1 level 2
event. All other drug-related AEs were level 1 or level 2 in
severity, with the exception of 1 SAE of abnormal liver
function tests in the motavizumab-only (control) group
that was reported by the investigator at the day 150 study
visit as level 4 in severity (reported as having returned to
Table 2: Comparison of adverse events overall and by severity
Mixed Motavizumab/
Palivizumab (n = 83)
Mixed Palivizumab/
Motavizumab (n = 83)
Motavizumab Only (n = 93)
Total number of AEs 405 408 459
Number (%) of children reporting:
≥1 AE 77 (92.8) 75 (90.4) 83 (89.2)
≥1 Level 1 AE, as the highest severity 17 (20.5) 26 (31.3) 22 (23.7)
≥1 Level 2 AE, as the highest severity 44 (53.0) 44 (53) 51 (54.8)
≥1 Level 3 AE, as the highest severity 13 (15.7) 5 (6.0) 6 (6.5)
≥1 Level 4 AE, as the highest severity 3 (3.6) 0 (0.0) 4 (4.3)
≥1 Related AE 14 (16.9) 16 (19.3) 21 (22.6)
≥1 SAE 19 (22.9)a 7 (8.4)a 11 (11.8)
≥1 Level 1 SAE, as the highest severity 1 (1.2) 0 (0.0) 0 (0.0)
≥1 Level 2 SAE, as the highest severity 4 (4.8) 4 (4.8) 4 (4.3)
≥1 Level 3 SAE, as the highest severity 11 (13.3)a 3 (3.6)a 4 (4.3)
≥1 Level 4 SAE, as the highest severity 3 (3.6) 0 (0.0) 3 (3.2)
≥1 Related SAE 2 (2.4) 0 (0.0) 1 (1.1)
≥1 AE resulting in discontinuation of 
study drug
3 (3.6) 0 (0.0) 0 (0.0)
≥1 Related AE resulting in 
discontinuation of study drug
2 (2.4) 0 (0.0) 0 (0.0)
Death 2 (2.4) 0 (0.0) 1 (1.1)b
aP < 0.05, mixed motavizumab/palivizumab vs. mixed palivizumab/motavizumab (2-sided Fisher's exact test; exploratory analysis only).
bThis patient withdrew consent on study day 13 and died on study day 153.Fernández et al. BMC Pediatrics 2010, 10:38
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Table 3: Adverse events occurring at ≥5% of any treatment group at any severity level
Mixed Motavizumab/
Palivizumab (n = 83)
Mixed Palivizumab/
Motavizumab (n = 83)
Motavizumab Only (n = 93)
Total number of AEs 405 408 459
Number (%) of subjects reporting ≥1 AE 77 (92.8) 75 (90.4) 83 (89.2)
Number (%) of subjects reporting AE by body systema
Blood and lymphatic system disorders
Anaemia 2 (2.4) 6 (7.2) 3 (3.2)
Eye disorders
Conjunctivitis 6 (7.2) 11 (13.3) 16 (17.2)
Gastrointestinal disorders
Constipation 6 (7.2) 6 (7.2) 7 (7.5)
Diarrhea 12 (14.5) 13 (15.7) 11 (11.8)
Gastroesophageal reflux disease 5 (6.0) 7 (8.4) 7 (7.5)
Inguinal hernia 0 (0.0) 4 (4.8) 5 (5.4)
Teething 10 (12.0) 9 (10.8) 16 (17.2)
General disorders and administration-site conditions
Injection site erythema 3 (3.6) 9 (10.8) 8 (8.6)
Irritability 10 (12.0) 11 (13.3) 11 (11.8)
Pyrexia 6 (7.2) 8 (9.6) 11 (11.8)
Infections and infestations
Bronchiolitis 11 (13.3) 7 (8.4) 5 (5.4)
Bronchitis 12 (14.5) 13 (15.7) 13 (14.0)
Bronchitis acute 3 (3.6) 7 (8.4) 6 (6.5)
Gastroenteritis 8 (9.6) 4 (4.8) 5 (5.4)
Lower respiratory tract infection 7 (8.4) 7 (8.4) 6 (6.5)
Nasopharyngitis 25 (30.1) 26 (31.3) 23 (24.7)
Oral candidiasis 2 (2.4) 5 (6.0) 2 (2.2)
Otitis media acute 2 (2.4) 0 (0.0) 5 (5.4)
Pharyngitis 7 (8.4) 4 (4.8) 10 (10.8)
Rhinitis 10 (12.0) 14 (16.9) 8 (8.6)
Upper respiratory tract infection 17 (20.5) 16 (19.3) 18 (19.4)
Laboratory investigation abnormalities
Alanine aminotransferase increased 1 (1.2) 1 (1.2) 5 (5.4)
Nervous system disorders
Hypertonia 5 (6.0) 1 (1.2) 0 (0.0)
Respiratory, thoracic, and mediastinal disorders
Cough 6 (7.2) 4 (4.8) 5 (5.4)
Nasal congestion 7 (8.4) 1 (1.2) 3 (3.2)
Rhinorrhoea 3 (3.6) 5 (6.0) 1 (1.1)
Wheezing 15 (18.1) 8 (9.6) 10 (10.8)
Skin and subcutaneous disorders
Dermatitis diaper 5 (6.0) 10 (12.0) 10 (10.8)
Eczema 1 (1.2) 5 (6.0) 4 (4.3)
Rash 3 (3.6) 5 (6.0) 4 (4.3)
Seborrhoeic dermatitis 4 (4.8) 1 (1.2) 5 (5.4)
aMedDRA (version 9.1) system organ classes and preferred terms are shown.Fernández et al. BMC Pediatrics 2010, 10:38
http://www.biomedcentral.com/1471-2431/10/38
Page 8 of 13
normal as of 142 days after the child received the fifth and
final dose of motavizumab).
SAEs Judged by the Site Investigators as Related to Study 
Treatment
Three SAEs were considered to be possibly or probably
related to study treatment by the site investigators: visual
disturbance, erythema multiforme (1 subject each; M/P
group), and abnormal liver function tests (1 subject, mot-
avizumab-only [control] group). Each subject had
received only motavizumab before the onset of each SAE.
The child with the reported event of visual disturbance
was a 5-month-old male with a gestational age of 26
weeks, and a medical history of respiratory distress syn-
drome, bronchopulmonary dysplasia, necrotizing entero-
colitis, gastroesophageal reflux, and intestinal
obstruction. He had an initial retinopathy of prematurity
screening at 6 weeks of age that was normal. He had
received only 1 dose of motavizumab before the event.
Two days after receiving motavizumab, the child was
noted to have abnormal roving eye movements, which
were random and not associated with any alteration in
sensorium or vital signs. The event of visual disturbance
Table 4: Overview of safety data before and after dose 3
Before Dose 3 After Dose 3
Mixed 
Motavizuma
b/
Palivizumab 
(n = 83)
Mixed 
Palivizumab/
Motavizuma
b (n = 83)
Motavizuma
b Only (n = 
93)
Mixed 
Motavizuma
b/
Palivizumab 
(n = 78a)
Mixed 
Palivizumab/
Motavizuma
b (n = 82a)
Motavizuma
b Only (n = 
92a)
AEs, n 175 186 204 230 222 255
Subjects 
reporting, n 
(%)
≥1 AE 66 (79.5) 64 (77.1) 69 (74.2) 70 (89.7) 68 (82.9) 71 (77.2)
≥1 Level 3 
AE as 
highest 
severity
3 (3.6) 3 (3.6) 1 (1.1) 10 (12.8) 3 (3.7) 5 (5.4)
≥1 Level 4 
AE
3 (3.6)b 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 3 (3.3)b
≥1 
Related 
AE
13 (15.7) 9 (10.8) 13 (14.0) 6 (7.7) 11 (13.4) 15 (16.3)
≥1 SAE 10 (12.0) 4 (4.8) 6 (6.5) 12 (15.4) 5 (6.1) 6 (6.5)
≥1 
Related 
SAE
2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1)
≥1 AE 
resulting 
in 
discontin
uation of 
study 
drug
2 (2.4)c 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Death 2 (2.4) 0 (0.0) 1 (1.1)d 0 (0.0) 0 (0.0) 0 (0.0)
aThe total number of subjects who received at least 3 doses of study drug.
bNone of the subjects who reported a level 4 AE had a level 3 AE.
cIncludes 1 subject with an SAE of visual disturbance who discontinued after 1 dose (followed to the end of the study period by an 
ophthalmologist, but did not complete the study follow-up) and 1 subject with an SAE of erythema multiforme who discontinued after 2 
doses (followed to the end of the study period and completed the study follow-up). A third subject experienced staphylococcal scalded skin 
syndrome after receiving 3 doses and also completed the study follow-up. All 3 subjects are included in the safety population.
dThis subject withdrew consent on study day 13 and died on study day 153.Fernández et al. BMC Pediatrics 2010, 10:38
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was reported by the investigator as an SAE of level 2
severity and was judged to be possibly related to study
treatment because of the temporal relationship, and study
drug was permanently discontinued. The child was with-
drawn from the study but was monitored by an ophthal-
mologist through study day 150, with the visual
disturbance still present. There was no formal diagnosis
of his visual abnormality. The child with the event of ery-
thema multiforme was a 2-month-old male with a gesta-
tional age of 34 weeks and a history of wet lung,
hyperbilirubinemia, bilateral pyelectasis, anemia of pre-
maturity, and seborrheic dermatitis. He had previously
taken cefadroxil, but not for the preceding 10 days. Two
days after the second dose of motavizumab he experi-
enced an abdominal rash. Four days after receiving mot-
avizumab he presented to the investigational site with a
generalized rash that was felt to be consistent with ery-
thema multiforme. There were no respiratory symptoms
or mucosal involvement, and his general condition was
good. A diagnosis of erythema multiforme minor was
made. He was treated with chlorpheniramine with reso-
lution of the rash 2 days later. This event was reported as
an SAE of level 2 severity and judged by the investigator
to be probably related to study treatment, and study drug
was permanently discontinued after its occurrence.
Study treatment was permanently discontinued
because of an AE in a total of 3 patients (all in the M/P
group). These included the events of visual disturbance
and erythema multiforme, which are described above,
and another child who experienced a level 3 SAE of
staphylococcal scalded skin syndrome, which the investi-
gator considered remotely related to study treatment.
This event occurred 3 days after this child received the
third dose of study drug (2 doses motavizumab and 1
dose palivizumab). The child's condition improved
quickly and resolved after receiving antibiotics for
bullous impetigo, and a dermatologist and infectious dis-
ease consultant felt that the clinical picture was consis-
tent with staphylococcal scalded skin syndrome. This
child and the child with erythema multiforme were mon-
itored through the end of the study period.
Deaths
There were 2 deaths during the study (one case of pneu-
monia and one case of sepsis). Both subjects were in the
M/P treatment group and both deaths occurred before
receiving palivizumab. The child who died from pneumo-
nia was born prematurely at 29 weeks' gestation with a
medical history significant for CLD, apnea of prematu-
rity, and previous infection. She received 2 doses of mot-
avizumab, the last dose administered 13 days before her
death. She was found not breathing on the morning of her
death; autopsy findings were consistent with acute bron-
chopneumonia. The child who died from sepsis had a
gestational age of approximately 35 weeks with a history
of suspected sepsis at birth. She had received 1 dose of
motavizumab 3 days before her death at 10 days of age.
On the day of her death, she was found not breathing
while sleeping in bed with her parents; autopsy findings
were consistent with sepsis and included hepatitis, septic
adrenalitis, and neonatal pneumonia. Neither child had a
known diagnosis of RSV at the time of death, and both
deaths were considered by the investigator to be unre-
lated to study treatment. A third child died on study day
153 of an intestinal obstruction. The child had received 1
dose of motavizumab at the time of withdrawal. This
death occurred outside of the study period, 140 days after
withdrawal of consent and beyond the AE follow-up
period (day 150). It was not considered by the site investi-
gator to be related to study drug and is presented here for
completeness.
Antimotavizumab and Antipalivizumab Antibodies
Few subjects developed detectable antibodies to either
study drug; ADA titers observed at different time points
during the study are illustrated in Figure 2. A total of 13
subjects (M/P, n = 8; P/M, n = 4; motavizumab only, n =
1) had detectable antipalivizumab and/or antimotavi-
zumab antibody at any time during the study. All antimo-
tavizumab antibodies were detected at study day 150 and/
or 270-300 (except 1 subject in the P/M group who had
antimotavizumab antibody detected at baseline prior to
receiving study drug, and had no subsequent antibody
detection after exposure to study drug). The subject in
the M/P group with the SAE of erythema multiforme on
study day 28 described above had antimotavizumab anti-
body of 1:50 detected on study day 150. Antimotavi-
zumab antibody titers ranged from 1:40 to 1:1250 in the
M/P treatment group and from 1:10 to 1:250 in the P/M
treatment group. Antipalivizumab antibody titers were
also low, ranging from 1:10 to 1:20 and were generally
detected at study day 150 and/or 270-300. Cross-reactiv-
ity was low (1.1-1.3%). Only 1 subject each in the M/P
and the motavizumab-only (control) treatment groups
had detectable antipalivizumab antibodies without
receiving palivizumab. The antipalivizumab titers of
these subjects were low (≤1:20).
Serum Drug Trough Concentrations
Mean serum trough concentrations of motavizumab and
palivizumab for each treatment group are illustrated in
Figure 3. As expected, serum concentrations of each drug
increased with treatment. On study day 60, mean serum
trough concentrations of motavizumab in the M/P and
motavizumab-only (control) groups were 74.74 μg/mL
and 78.02 μg/mL, respectively. On study day 150, mean
serum trough concentrations of motavizumab in the P/M
and motavizumab-only (control) groups were 93.05 μg/Fernández et al. BMC Pediatrics 2010, 10:38
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mL and 105.8 μg/mL, respectively. For palivizumab, the
mean serum trough concentration in the P/M group was
87.37 μg/mL on day 60.
Discussion
In this small study evaluating the safety and tolerability of
motavizumab and palivizumab administered sequentially
during the same season for RSV prophylaxis, both study
d r u g s  w e r e  f o u n d  t o  h a v e  a n  a c c e p t a b l e  s a f e t y  p r o f i l e .
Over 90% of subjects in the 3 treatment groups received
all 5 doses of study drug and completed the study. Over-
all, the rates of AEs were similar among all 3 treatment
groups. The most frequent AEs were infectious in nature,
and were events common to and expected in this high-
risk pediatric population. Of interest was the increased
rate of level 3 AEs and SAEs in the M/P treatment group
compared with the other treatment groups. This differ-
ence was present both before dose 3 (motavizumab for 2
doses) and after dose 3 (palivizumab for 3 doses), suggest-
ing a cause other than receipt of both study drugs. In
addition, before the switch from motavizumab to palivi-
zumab, the rates of level 3 AEs as the highest severity,
level 4 AEs, SAEs, SAEs judged by the site investigator to
be related to study drug, and AEs that resulted in discon-
tinuation of study drug were higher among children in
the M/P group than in the motavizumab-only (control)
group, again suggesting a difference that could not be
explained by study treatment since both groups had
received the same drug and number of doses.
When the increased incidence of SAEs in the M/P
treatment group was further evaluated, it was noted that
the increase in either time period was attributable to
SAEs in the MedDRA "infections and infestations" system
organ class. Since this was not an efficacy study, formal
study data on RSV infections were not collected. How-
ever, some sites performed local RSV testing and
reported the results. Of the 10 children in the M/P group
with SAEs of respiratory infections who had local viral
testing reported, 2 tests were positive for RSV. In addi-
tion, half of the SAEs in the M/P group occurred before
d o s e  3  ( i e ,  w h e n  s u b j e c t s  h a d  r e c e i v e d  o n l y  m o t a v i -
zumab). For the 3 SAEs that were judged by the site inves-
tigators to be related to study treatment, all occurred
after the receipt of motavizumab only.
Figure 2 Antimotavizumab and antipalivizumab antibodies detected during the study. Antimotavizumab titers ranged from 1:40 to 1:1250 in 
the mixed motavizumab/palivizumab treatment group and from 1:10 to 1:250 in the mixed palivizumab/motavizumab treatment group. Final anti-
body assessments at days 270 to 300 correspond to 120-150 days after the final dose.
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Overall, antimotavizumab and antipalivizumab anti-
body detection was infrequent. A total of 13 subjects had
antipalivizumab and/or antimotavizumab antibody at any
time during the study, and no antimotavizumab antibody
was detected in any subject in the motavizumab-only
(control) treatment group. Mean serum trough concen-
trations of motavizumab and palivizumab in the mixed-
dose and motavizumab-only (control) treatment groups
were comparable based on the number of doses received.
Only one child had a reported event consistent with a
hypersensitivity reaction (erythema multiforme minor)
after 2 doses of motavizumab. This event subsequently
resolved; further study dosing was discontinued by the
site investigator. ADA was detected in this child on study
day 150, 124 days after final dose on study day 26. The
causal relation of ADA with the event cannot be deter-
mined. No other events that could be considered
immune-mediated were noted in children with and with-
out ADA.
The conclusions drawn from this study are limited by
the small sample size per group. Yet, in this group of
high-risk children, the rates of AEs, serum drug trough
concentrations, and occurrence of ADA associated with
the sequential administration of motavizumab and palivi-
zumab appear comparable to those observed in subjects
administered motavizumab alone during the same RSV
season.
While it did not address effects of sequential dosing, a
large clinical study by Carbonell-Estrany et al recently
compared the safety and efficacy of motavizumab (n =
3315) to palivizumab (n = 3298) and identified no signifi-
cant overall difference in subjects reporting at least 1 AE
(motavizumab, 85.6%; palivizumab, 86.0%), nor in sub-
jects reporting at least 1 SAE (motavizumab, 14.6%;
Figure 3 Serum trough concentrations for motavizumab and palivizumab. Data shown are mean (SD). The peak serum trough concentrations 
for each group reflect the sequence of dosing for that treatment group. Final serum concentrations (days 270-300) reflect those assessed 120-150 
days after the final dose. Serum trough concentrations below the lower limit of quantification (motavizumab, 1.563 μg/mL; palivizumab, 10 μg/mL) 
were reported as 0.
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palivizumab, 15.3%) [20]. The overall rates of AEs and
SAEs observed in the study by Carbonell-Estrany et al are
similar to those in our study. Regarding AEs in the Med-
DRA system organ class of "infections and infestations,"
the study by Carbonell-Estrany et al found rates that were
comparable for motavizumab and palivizumab. The chil-
dren who received motavizumab had an overall AE infec-
tion rate of 66.3% with an SAE infection rate of 8.2%. In
the palivizumab group, the overall AE infection rate was
68.3% with an SAE infection rate of 9.3% (G.A. Losonsky,
MedImmune, LLC, personal communication). It is likely
that differences among groups in our study could be
attributed to the small sample size and not to the study
drug administered or the sequence of administration.
Conclusions
In this small study, motavizumab and palivizumab
administered sequentially during the same RSV season
exhibited an acceptable safety profile in high-risk preterm
children. These results suggest that the safety, serum drug
trough concentrations, and ADA profiles of palivizumab
and motavizumab given in varying sequence are compa-
rable to those observed in subjects receiving only motavi-
zumab during the season.
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